A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
NCT07446101
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- May 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Fortrea Clinical Research Unit · Daytona Beach, FL
Minnesota · 1
- Axis Clinicals LLC · Dilworth, MN
Texas · 2
- Fortrea Clinical Research Unit · Dallas, TX
- Worldwide Clinical Trials, Inc. · San Antonio, TX
Wisconsin · 1
- Fortrea Clinical Research Unit · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.